Mydecine Innovations Group (OTCPK:MYCO.F) - Hisse Senedi Fiyatı, Haberler ve Analizler

MYCO.F Stoklara Genel Bakış

Bir biyoteknoloji şirketi olan Mydecine Innovations Group Inc. ruh sağlığı sorunlarını tedavi etmek için psilosibin ürünlerinin araştırılması, geliştirilmesi ve ticarileştirilmesiyle ilgilenmektedir. Daha fazla detay

MYCO.F temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 8.7% oranında arttı

Risk Analizi

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( $333K )

Negatif hissedar öz sermayesi

Geliri 1 milyon ABD dolarından az ( CA$0 )

+ 2 daha fazla risk

Mydecine Innovations Group Inc. Rakipler

Kid Castle Educational

OTCPK:KDCE

US$357.2k

TFF Pharmaceuticals

NasdaqCM:TFFP

US$1.4m

SciSparc

NasdaqCM:SPRC

US$790.0k

AmeriCann

OTCPK:ACAN

US$465.9k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Mydecine Innovations Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.0054
52 Haftanın En Yüksek Seviyesi	US$0.095
52 Haftanın En Düşük Seviyesi	US$0.0001
Beta	2.77
11 Aylık Değişim	42.11%
3 Aylık Değişim	-27.03%
1 Yıllık Değişim	-93.72%
33 Yıllık Değişim	-99.93%
5 Yıllık Değişim	-99.95%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	MYCO.F	US Pharmaceuticals	US Pazar
7D	-21.7%	2.6%	0.5%
1Y	-93.7%	13.1%	30.7%

Getiri vs. Endüstri: MYCO.F geçen yıl % 13.1 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: MYCO.F geçen yıl % 30.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MYCO.F's price volatile compared to industry and market?
MYCO.F volatility
MYCO.F Average Weekly Movement	104.7%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: MYCO.F hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: MYCO.F 'nin haftalık oynaklığı son bir yılda 2907% dan 105% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	3	Josh Bartch	www.mydecine.com

Bir biyoteknoloji şirketi olan Mydecine Innovations Group Inc. ruh sağlığı koşullarını tedavi etmek için psilosibin ürünlerinin araştırılması, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Şirket öncelikle nikotin bağımlılığı ve travma sonrası stres bozukluğu tedavisine odaklanmaktadır. Öncü ürün ilaç adayları arasında MYCO-005 bulunmaktadır.

Mydecine Innovations Group Inc. Temel Bilgiler Özeti

Mydecine Innovations Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MYCO.F temel i̇stati̇sti̇kler
Piyasa değeri	US$333.48k
Kazançlar(TTM)	-US$8.89m
Gelir(TTM)	n/a

0.0x

P/S Oranı

0.0x

F/K Oranı

MYCO.F aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MYCO.F gelir tablosu (TTM)
Gelir	CA$0
Gelir Maliyeti	CA$0
Brüt Kâr	CA$0
Diğer Giderler	CA$12.46m
Kazançlar	-CA$12.46m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.20
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	-37.4%

MYCO.F uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MYCO.F Stoklara Genel Bakış

Ödüller

Risk Analizi

Mydecine Innovations Group Inc. Rakipler

OTCPK:KDCE

US$357.2k

NasdaqCM:TFFP

US$1.4m

NasdaqCM:SPRC

US$790.0k

OTCPK:ACAN

US$465.9k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Recent updates

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group Launches Mindleap app

Mydecine Innovations Group Inc. Announces Appointment of Rakesh Jetly as Chief Medical Officer

Mydecine Innovations Group Inc. (CNSX:MYCO) completed the acquisition of NeuroPharm Inc.

NewLeaf Brands Inc. (CNSX:NLB) completed the acquisition of Mindleap Health.

Mydecine Innovations Group Inc. announced that it has received CAD 2.4 million in funding

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Mydecine Innovations Group Inc. Temel Bilgiler Özeti

0.0x